Pasithea Therapeutics Corp.
KTTA
$0.956
$0.095411.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.65% | -34.25% | -11.85% | 8.28% | -32.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.69% | -20.71% | 3.04% | 25.78% | 27.36% |
| Operating Income | 36.69% | 20.71% | -3.04% | -25.78% | -27.36% |
| Income Before Tax | 36.84% | 16.96% | -7.45% | -18.22% | -24.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.84% | 16.96% | -7.45% | -18.22% | -24.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 98.41% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.05% | 16.96% | -2.74% | -9.13% | 1.36% |
| EBIT | 36.69% | 20.71% | -3.04% | -25.78% | -27.36% |
| EBITDA | 37.89% | 21.64% | -3.17% | -27.13% | -23.47% |
| EPS Basic | 44.30% | -0.05% | -28.64% | -36.47% | -19.16% |
| Normalized Basic EPS | 43.91% | -0.05% | -34.55% | -47.84% | -103.53% |
| EPS Diluted | 44.30% | -0.05% | -28.64% | -36.47% | -19.16% |
| Normalized Diluted EPS | 43.91% | -0.05% | -34.55% | -47.84% | -103.53% |
| Average Basic Shares Outstanding | 2.27% | -17.01% | -20.14% | -20.04% | -2.83% |
| Average Diluted Shares Outstanding | 2.27% | -17.01% | -20.14% | -20.04% | -2.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |